-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Vancouver, British Columbia, September 24, 2021/PRNewswire/ - BioVaxys Technology Corp.
Many patients with new coronavirus infection will develop pneumonia, which may lead to acute respiratory distress, and some of them will experience cardiac symptoms and cardiovascular damage
S.
Dr.
James Passin, Chief Executive Officer of BioVaxys, said: “In the context of reports of (albeit rare) adverse reactions and significant reductions in immunity, public health authorities are considering the option of repeating seasonal vaccine boosters, and haptenization as a kind of The method of improving its immunogenicity while inhibiting the binding of the spike protein ACE2 may play a key role in the global strategy for the development and deployment of new coronary pneumonia vaccines
This week, BioVaxys reached an agreement with the Global Contract Development and Manufacturing Research Organization (CDMO) Millipore-Sigma (hereinafter referred to as "Millipore") to produce the GLP-grade BVX-0320 vaccine, which is the company's new coronavirus vaccine candidate for research
BioVaxys is currently finalizing a final arrangement with a major American academic research institution, which will collaborate with the company on this research
In order to provide greater certainty, BioVaxys makes no explicit or implicit statement about its current ability to treat the new coronavirus
1J Hematol Oncol 2020 Sep 4;13(1):120
About BioVaxys Technology Corp.
BioVaxys Technology Corp.
Representative board
Signed "James Passin"
Cautionary statement regarding forward-looking information
This press release contains certain "forward-looking information" and "forward-looking statements" (collectively referred to as "forward-looking statements") as defined in relevant Canadian and U.
These forward-looking statements reflect the views, opinions and forecasts as of the date of the statement, and are based on certain assumptions and estimates
Unless required by law, the company has no obligation to update relevant forward-looking statements based on changes in opinions, opinions, forecasts or other factors
